Study to Assess Efficacy and Safety of SZC for the Management of High Potassium in Patients With Symptomatic HFrEF Receiving Spironolactone

PHASE4CompletedINTERVENTIONAL
Enrollment

366

Participants

Timeline

Start Date

March 8, 2021

Primary Completion Date

July 15, 2024

Study Completion Date

July 15, 2024

Conditions
HyperkalaemiaHeart Failure With Reduced Ejection Fraction
Interventions
DRUG

Sodium zirconium cyclosilicate

Investigational medicinal product

DRUG

Placebo

Placebo comparator

OTHER

Spironolactone

"Background intervention.~During the run-in phase, spironolactone will be initiated/uptitrated up to a maximum of 50 mg per day. During the randomized withdrawal phase the spironolactone dose at the end of the run-in phase will be maintained."

Trial Locations (89)

1122

Research Site, Budapest

1204

Research Site, Budapest

4009

Research Site, Almería

8035

Research Site, Barcelona

8041

Research Site, Barcelona

8900

Research Site, Zalaegerszeg

10029

Research Site, New York

15006

Research Site, A Coruña

15706

Research Site, Santiago de Compostela

18007

Research Site, Granada

21005

Research Site, Huelva

22042

Research Site, Falls Church

23007

Research Site, Jaén

25198

Research Site, Lleida

27157

Research Site, Winston-Salem

28041

Research Site, Madrid

28222

Research Site, Majadahonda

29605

Research Site, Greenville

30120

Research Site, Murcia

31008

Research Site, Pamplona

36532

Research Site, Fairhope

37007

Research Site, Salamanca

41009

Research Site, Seville

41013

Research Site, Seville

46010

Research Site, Valencia

46026

Research Site, Valencia

48013

Research Site, Bilbao (Vizcaya)

50009

Research Site, Zaragoza

55001

Research Site, Broumov

55101

Research Site, Jaroměř

60202

Research Site, Evanston

60453

Research Site, Oak Lawn

64111

Research Site, Kansas City

68601

Research Site, Uherské Hradiště

77054

Research Site, Houston

90033

Research Site, Los Angeles

90502

Research Site, Torrance

60429-2196

Research Site, Hazel Crest

30110-017

Research Site, Belo Horizonte

12916-542

Research Site, Bragança Paulista

70390-700

Research Site, Brasília

71615-907

Research Site, Brasília

83430-000

Research Site, Campina Grande do Sul

13060-080

Research Site, Campinas

92425-020

Research Site, Canoas

89201-490

Research Site, Joinville

90020-090

Research Site, Porto Alegre

90035-000

Research Site, Porto Alegre

90035-903

Research Site, Porto Alegre

14026-020

Research Site, Ribeirão Preto

41810-011

Research Site, Salvador

96835-090

Research Site, Santa Cruz do Sul

01321-001

Research Site, São Paulo

04556-100

Research Site, São Paulo

05652-9000

Research Site, São Paulo

08270-070

Research Site, São Paulo

15500-003

Research Site, Votuporanga

N1R 6V6

Research Site, Cambridge

N2N 1B2

Research Site, Kitchener

M1B 4Z8

Research Site, Scarborough Village

M1S 4N6

Research Site, Scarborough Village

M5B1M8

Research Site, Toronto

L1N 5T2

Research Site, Whitby

H1T 1C8

Research Site, Montreal

H2X 3E4

Research Site, Montreal

G1R 2J6

Research Site, Québec

J6V 2H2

Research Site, Terrebonne

250 01

Research Site, Brandýs nad Labem

500 02

Research Site, Hradec Králové

440 01

Research Site, Louny

708 52

Research Site, Ostrava

81-157

Research Site, Gdynia

90-553

Research Site, Lodz

91-002

Research Site, Lodz

93-513

Research Site, Lódz

60-185

Research Site, Skórzewo

58-130

Research Site, Żarów

07010

Research Site, Palma de Mallorca

07198

Research Site, Palma de Mallorca

08208

Research Site, Sabadell

NE63 9JJ

Research Site, Ashington

CF31 1RQ

Research Site, Bridgend

BS105NB

Research Site, Bristol

G4 0SF

Research Site, Glasgow

LE3 9QP

Research Site, Leicester

L9 7AL

Research Site, Liverpool

M13 9WL

Research Site, Manchester

NP20 2UB

Research Site, Newport

S5 7AU

Research Site, Sheffield

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY